Motilal Oswal Recommends 'Buy' on Ajanta Pharma; Sets Rs 3145 Target

• Motilal Oswal reiterates 'Buy' rating for Ajanta Pharma with a target price of INR3,145.
• AJP is implementing strategic initiatives across India, Asia, and Africa for robust growth.
• Focus on expanding therapy coverage and shifting to chronic indications in emerging markets.
• Company aims to add new geographies and enhance product offerings in existing markets.
• Partnership with Biocon for semaglutide in 23 countries is a key step for new therapies.

Why It Matters: Motilal Oswal recommends buying Ajanta Pharma, citing strong strategic initiatives and a target of INR3,145.